CHI Advisors’s Larimar Therapeutics LRMR Stock Holding History

CHI Advisors’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$13.5M	Hold	3,414,468	–	–	5.35%	6
2023 Q2	$8.72M	Buy	3,414,468 +668,203	+24%	+$2.73M	2.65%	9
2023 Q1	$12.4M	Sell	2,746,265 -727,101	-21%	-$3.8M	3.3%	6
2022 Q4	$14.3M	Buy	3,473,366 +58,218	+2%	+$199K	3.82%	6
2022 Q3	$10.9M	Buy	3,415,148 +1,900,000	+125%	+$4.76M	2.94%	7
2022 Q2	$2.97M	Hold	1,515,148	–	–	1.13%	19
2022 Q1	$6.14M	Hold	1,515,148	–	–	2.61%	8
2021 Q4	$16.3M	Hold	1,515,148	–	–	5.43%	5
2021 Q3	$17.5M	Hold	1,515,148	–	–	5.1%	7
2021 Q2	$14.9M	Hold	1,515,148	–	–	3.46%	9
2021 Q1	$22.1M	Hold	1,515,148	–	–	4.43%	9
2020 Q4	$32.4M	Hold	1,515,148	–	–	9.14%	4
2020 Q3	$23M	Hold	1,515,148	–	–	8.18%	4
2020 Q2	$19.5M	Buy	+1,515,148	New	+$17.6M	7.6%	5

Other funds holding LRMR

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

CHI Advisors's LRMR Position: Q3 2023 in Review

CHI Advisors held its Larimar Therapeutics (LRMR) position steady in Q3 2023 at 3,414,468 shares worth $13.5M. The position accounts for 5.35% of the portfolio, ranked #6.

CHI Advisors first reported a position in LRMR in Q2 2020 and has held it in 14 quarters since. The position peaked at $32.4M in Q4 2020. 65 funds tracked by Wall St. Rank hold LRMR as of Q3 2023.

CHI Advisors held 3,414,468 shares of Larimar Therapeutics worth $13.5M as of Q3 2023.
CHI Advisors left its Larimar Therapeutics share count unchanged in Q3 2023.
Larimar Therapeutics made up 5.35% of CHI Advisors's portfolio in Q3 2023, its #6 holding.
CHI Advisors first reported a position in Larimar Therapeutics in Q2 2020 and has held it in 14 quarters since.
CHI Advisors's Larimar Therapeutics position peaked at $32.4M in Q4 2020.
65 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2023.

Based on CHI Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.